|Videos|December 15, 2020
Overview of the PIONEER Clinical Trial Program for Oral Semaglutide
Results from the PIONEER clinical trials program indicate that the first oral glucagon-like peptide-1 receptor agonist (GLP-1RA), oral semaglutide, provides effective glycemic control across a range of different patient populations.
Click PLAY to watch the video abstract.
Click
Click
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Content
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
How Do GLP-1 Agonists Fit Into Stroke Care?
3
Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD
4
Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making
5
